ACTIVE HALF-LIFE
2 days
CLASSIFICATION
Non-steroidal aromatase inhibitor
DOSAGE
0.5 - 2.5 mg/day
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Beligas - US
LAB TEST
See Document
WAREHOUSE
USA Warehouse 2
SUBSTANCE
Letrozole
Introducing Mono-Femara, a cutting-edge non-steroidal aromatase inhibitor renowned for its potent anticancer properties. As a third-generation aromatase inhibitor, it effectively and reversibly blocks aromatase, a key enzyme that fuels the growth of estrogen-dependent breast cancer cells. This makes it a crucial ally in the fight against hormone receptor-positive and unknown receptor status breast cancer in postmenopausal women, as approved by the FDA.
Aromatase, a cytochrome P-450 enzyme located in various tissues such as the ovaries, liver, and breasts, catalyzes the conversion of androgens into estrogens, namely estrone and estradiol. By competitively binding to the enzyme?s heme component, Mono-Femara halts estrogen production without affecting the synthesis of mineralocorticoids or corticosteroids. Unlike tamoxifen, which blocks estrogen receptors, Mono-Femara directly inhibits estrogen synthesis, offering a unique approach to treatment.
With the ability to lower estrogen levels by up to 98% while simultaneously boosting testosterone, Mono-Femara is also popular among athletes and bodybuilders. It helps alleviate water retention and prevent gynecomastia during anabolic steroid cycles. However, it?s important to note that dosages exceeding 2.5 mg/day may temporarily diminish libido, and prolonged use above 5 mg/day can pose kidney risks.
Moreover, Mono-Femara has been shown to delay the fusion of growth plates in adolescents, potentially enhancing the efficacy of growth hormone, making it a valuable option for addressing short stature in children and teens. While it may lead to some side effects associated with low estrogen levels, such as osteoporosis concerns, doctors often recommend complementary medications like Fosamax to mitigate these risks.